Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 4/20 | 0.55 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | WNT3A | P56704 | 4/20 | 0.47 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1749310 | 1.00 | SRC (0.55) | SRCTP53WNT3ATRPC5RXFP1 | |
| SCHEMBL255177 | 0.99 | SRC (0.56) | SRCTP53WNT3ATRPC5RXFP1 | |
| SCHEMBL255223 | 0.90 | SRC (0.55) | SRCTP53WNT3ARAB9AMAPK1 | |
| SCHEMBL254478 | 0.89 | SRC (0.61) | SRCWNT3ATRPC5RAB9AMAPK1 | |
| SCHEMBL29580134 | 0.89 | SRC (0.61) | SRCWNT3ATRPC5RAB9AMAPK1 | |
| SCHEMBL12782353 | 0.88 | HTT (0.49) | TP53HTTMAPTTHRBRAB9A | |
| SCHEMBL254295 | 0.88 | SRC (0.65) | SRCWNT3ATRPC5RAB9AMAPK1 | |
| SCHEMBL254165 | 0.85 | SRC (0.72) | SRCWNT3ATRPC5RAB9AMAPK1 | |
| SCHEMBL254590 | 0.84 | SRC (0.66) | SRCWNT3ATRPC5RAB9AMAPK1 | |
| SCHEMBL29580802 | 0.84 | SRC (0.63) | SRCTP53WNT3ATRPC5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9580387-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-8980890-B2 | Compositions and methods of treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140213587-A1 | Biaryl Compositions and Methods for Modulating a Kinase Cascade | KINEX PHARMACEUTICALS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-8236799-B2 | Biaryl compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1836169-B9 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | KINEX PHARMACEUTICALS LLC (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1836169-B1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | KINEX PHARMACEUTICALS LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110237586-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2011-09-29 | — | — | US | disclosed |
| US-8003641-B2 | Compositions and methods of treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110065705-A1 | Compositions and Methods of Treating Cell Proliferation Disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2011-03-17 | — | — | US | disclosed |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | SRC 116/4885ROCK2 312/4885TP53 560/4885 |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | MKI67, PCNA, CCAR2 | SRC 3344/4885ROCK2 878/4885TP53 99/4885 |
| US-20140213587-A1 | Biaryl Compositions and Methods for Modulating a Kinase Cascade | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885ROCK2 293/4885TP53 514/4885 |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885ROCK2 293/4885TP53 514/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885ROCK2 293/4885TP53 514/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | SRC 112/4885ROCK2 281/4885TP53 694/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885ROCK2 293/4885TP53 514/4885 |
| US-20110237586-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | BMP2K, MAP3K1, MAP3K20 | SRC 106/4885ROCK2 349/4885TP53 2051/4885 |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | MKI67, CCNC, CCNA1 | SRC 430/4885ROCK2 283/4885TP53 30/4885 |
| US-20110065705-A1 | Compositions and Methods of Treating Cell Proliferation Disorders | MKI67, CCNC, CCNA1 | SRC 430/4885ROCK2 283/4885TP53 30/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | SRC 430/4885ROCK2 283/4885TP53 30/4885 |
| US-20100249130-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K3, MAP3K6 | SRC 112/4885ROCK2 281/4885TP53 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.